Industry
Biotechnology
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Loading...
Open
23.08
Mkt cap
1.7B
Volume
299K
High
23.41
P/E Ratio
-191.75
52-wk high
28.15
Low
22.68
Div yield
N/A
52-wk low
14.12
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 11:35 am
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 8:32 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 01, 2024 | 2:47 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 5:39 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 11:32 am
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 10:57 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.